Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
haMPC-Exos for Carbapenem-resistant Pulmonary Infection
NCT04544215Phase 2Suspended
- Sponsor
- Ruijin Hospital
- Start
- Jul 2020
- Primary completion
- Dec 2024
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of human amnion-derived mesenchymal progenitor cell exosomes in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), sponsored by Ruijin Hospital. Started Jul 2020; status: suspended.
02
Drugs
human amnion-derived mesenchymal progenitor cell exosomes
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT04544215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544215.